ATE428412T1 - Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten - Google Patents

Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten

Info

Publication number
ATE428412T1
ATE428412T1 AT03709127T AT03709127T ATE428412T1 AT E428412 T1 ATE428412 T1 AT E428412T1 AT 03709127 T AT03709127 T AT 03709127T AT 03709127 T AT03709127 T AT 03709127T AT E428412 T1 ATE428412 T1 AT E428412T1
Authority
AT
Austria
Prior art keywords
urea
derivatives
treatment
compound
eye diseases
Prior art date
Application number
AT03709127T
Other languages
English (en)
Inventor
Vicken Karageozian
David Castillejos
John Park
Original Assignee
Vitreo Retinal Technologies In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies In filed Critical Vitreo Retinal Technologies In
Application granted granted Critical
Publication of ATE428412T1 publication Critical patent/ATE428412T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT03709127T 2002-02-13 2003-02-13 Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten ATE428412T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35734702P 2002-02-13 2002-02-13
US35757402P 2002-02-15 2002-02-15
PCT/US2003/004617 WO2003068166A2 (en) 2002-02-13 2003-02-13 Treatment of ophthalmic disorders using urea and urea derivatives

Publications (1)

Publication Number Publication Date
ATE428412T1 true ATE428412T1 (de) 2009-05-15

Family

ID=27737587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709127T ATE428412T1 (de) 2002-02-13 2003-02-13 Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten

Country Status (15)

Country Link
EP (1) EP1480678B1 (de)
JP (1) JP2005521681A (de)
KR (1) KR20040094687A (de)
CN (1) CN1633308A (de)
AT (1) ATE428412T1 (de)
AU (1) AU2003213084B2 (de)
BR (1) BR0307611A (de)
CA (1) CA2475338C (de)
DE (1) DE60327179D1 (de)
ES (1) ES2325360T3 (de)
IL (1) IL163374A (de)
MX (1) MXPA04007802A (de)
NZ (1) NZ535165A (de)
RU (1) RU2339369C2 (de)
WO (1) WO2003068166A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
AU2003213858A1 (en) * 2002-03-14 2003-09-29 Vitreo-Retinal Technologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to macular and retinal cells using liposome constructs
US10632211B2 (en) * 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908063D0 (en) * 1989-04-11 1989-05-24 Beecham Group Plc Novel compounds
ES2204920T3 (es) * 1993-05-27 2004-05-01 Cenes Limited Guanidinas substituidas terapeuticas.
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
AU705487B2 (en) * 1993-11-23 1999-05-20 Cambridge Neuroscience, Inc. Therapeutic substituted guanidines
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
US6395758B1 (en) * 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
AU780299B2 (en) * 1999-03-02 2005-03-17 Numoda Biotechnologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6337350B1 (en) * 1999-04-05 2002-01-08 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
AU2003213084B2 (en) 2008-06-26
BR0307611A (pt) 2004-12-21
NZ535165A (en) 2006-08-31
RU2004127610A (ru) 2005-06-27
CA2475338C (en) 2014-08-19
WO2003068166A2 (en) 2003-08-21
ES2325360T3 (es) 2009-09-02
DE60327179D1 (de) 2009-05-28
AU2003213084A1 (en) 2003-09-04
RU2339369C2 (ru) 2008-11-27
CA2475338A1 (en) 2003-08-21
EP1480678B1 (de) 2009-04-15
KR20040094687A (ko) 2004-11-10
MXPA04007802A (es) 2005-04-19
WO2003068166A3 (en) 2003-12-24
IL163374A (en) 2012-01-31
CN1633308A (zh) 2005-06-29
EP1480678A4 (de) 2005-08-24
JP2005521681A (ja) 2005-07-21
EP1480678A2 (de) 2004-12-01

Similar Documents

Publication Publication Date Title
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE68902649D1 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
NO20035743L (no) Substituerte oksazolindinoner for kombinasjonsterapi
ATE467616T1 (de) Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
ATE489379T1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
ATE361918T1 (de) 4-(4-methoxybenzyl)-n&#39;-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
DE60327179D1 (de) Behandlung von augenkrankheiten mit harnstoff und harnstoffderivaten
DE69524780D1 (de) Verwendung von indolderivaten zur behandlung von dermatologischen krankheiten, peridhren neuropathien, arthritis, allergischen oder chronisch-obstruktiven atemwegserkrankungen, glaukom und augenentzündungen
BRPI0412131A (pt) métodos de tratamento de distúrbios oftálmicos, para evitar hemorragia retìnica, perda de acuidade visual, reduzir exsudatos duros e retardar progressão de dano retìnico
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
NO20030021L (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE69910706D1 (de) Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties